Malaysia-based Hovid seeks US FDA nod for tocotrienols


PETALING JAYA: Investors may have overlooked Hovid Bhd’s pharmaceutical business and efforts to register tocotrienols (a type of Vitamin E) as a US Food and Drug Administration (FDA)-approved drug, said CIMB Investment Bank Bhd in a report.

It is currently sold as a dietary supplement under the brand name “Tocovid” but unlike drugs, dietary supplements cannot make the claim of being able to prevent, treat or cure illnesses due to regulatory restrictions.

“Hovid is seeking approval from the US FDA to sell Tocovid as a drug that could aid stroke patients. A mid-stage clinical trial would be carried out soon and the company is hopeful of obtaining approval as soon as in the next three to five years,” the report said.

The pharmaceutical company does not produce tocotrienols but owns the formulation patent that facilitates the absorption of tocotrienols by the human body. It would be sourced from its phytonutrient production arm, Carotech.

The bank-backed research house also said the approval would help the company increase its earnings. This is due to the unavailability of specific treatment to reduce brain damage in stroke patients.

The company exports to over 50 countries, with 52.5% of revenue in financial year 2013 consisting of exports.

The report also added that the next five years would see drug patents worth US$133bil in annual sales expire. “This allows Hovid to launch the generic versions of these drugs and expand its sales,” it said.

This is seen as another catalyst for Hovid, which started out as a herbal tea-maker in 1941 and started producing generic drugs in the 1980s.

Apart from the overseas front, the report added that Hovid would also gain from the Government’s plan to grant a three-year offtake agreement (OTA) via the Health Ministry to new generic drugs that were manufactured locally.

The OTA is extendable by another two years if the drug is exported. Currently, around 10% of its sales go to the ministry.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3

Business , hovid , drugs

   

Did you find this article insightful?

Yes
No

Next In Business News

Oil soars to near 14-month high as Opec+ extends output cuts into April
China blue-chip index ends lower after Beijing sets conservative growth target
Japanese investors dump record amount of foreign bonds
Jamaludin, Gita appointed to Axiata advisory panel
HSBC Malaysia continues to see great opportunities in commercial banking
China to speed up tapping new energy sources, but coal stays in mix
Suhaili Idrus appointed chairman of MPRC
MPHB Capital unit still in talks to sell stake in MPI Generali
MARC upgrades QSP Semenanjung’s RM1b sukuk
KLCI remains caught in consolidation

Stories You'll Enjoy


Vouchers